Fixed-dose combination lercanidipine/enalapril (Q36702083)

15 August 2017

1 reference

title

Fixed-dose combination lercanidipine/enalapril (English)

1 reference

15 August 2017

3

Caroline M Perry

1 reference

15 August 2017

2

Lesley J Scott

1 reference

15 August 2017

Philip I Hair

1

1 reference

15 August 2017

publication date

1 January 2007

1 reference

15 August 2017

1 reference

15 August 2017

volume

67

1 reference

15 August 2017

issue

1

1 reference

15 August 2017

page(s)

95-106; discussion 107-8

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200767010-00007

15 August 2017

exact match

0 references

cites work

Angiotensin-converting enzyme inhibition with enalapril slows progressive intima-media thickening of the common carotid artery in patients with non-insulin-dependent diabetes mellitus

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200767010-00007

Angiotensin-Converting Enzyme Inhibitors

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200767010-00007

Effect of 3 years of antihypertensive therapy on renal structure in type 1 diabetic patients with albuminuria: the European Study for the Prevention of Renal Disease in Type 1 Diabetes (ESPRIT)

21 January 2018

1 reference

12 December 2020

Lithium and angiotensin-converting enzyme inhibitors: evaluation of a potential interaction

1 reference

12 December 2020

Increased vascular selectivity and prolonged pharmacological efficacy of the L-type Ca2+ channel antagonist lercanidipine in human cardiovascular tissue

1 reference

12 December 2020

Advantages of blood pressure optimization

1 reference

12 December 2020

The new calcium antagonist lercanidipine and its enantiomers affect major processes of atherogenesis in vitro: is calcium entry involved?

1 reference

12 December 2020

2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension

1 reference

12 December 2020

Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial

1 reference

12 December 2020

Lercanidipine: a review of its use in hypertension

1 reference

12 December 2020

In vitro inhibitory effect of lercanidipine on cholesterol accumulation and matrix metalloproteinases secretion by macrophages

1 reference

12 December 2020

Effect of treatment with candesartan or enalapril on subcutaneous small artery structure in hypertensive patients with noninsulin-dependent diabetes mellitus

1 reference

12 December 2020

Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes

1 reference

12 December 2020

Lercanidipine in patients with chronic renal failure: the ZAFRA study

1 reference

12 December 2020

Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive Type 2 diabetic patients with microalbuminuria: DIAL study (diabete, ipertensione, albuminuria, lercanidipina).

1 reference

12 December 2020

Lercanidipine : a review of its efficacy in the management of hypertension

1 reference

12 December 2020

Effect of lercanidipine and its (R)-enantiomer on atherosclerotic lesions induced in hypercholesterolemic rabbits.

1 reference

12 December 2020

Enalapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure

1 reference

12 December 2020

Efficacy and safety of lercanidipine versus hydrochlorothiazide as add-on to enalapril in diabetic populations with uncontrolled hypertension

1 reference

12 December 2020

Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats

1 reference

12 December 2020

The effect of enalapril on serum lithium levels in healthy men

1 reference

12 December 2020

Effect of calcium antagonists on glomerular arterioles in spontaneously hypertensive rats

1 reference

12 December 2020

Expanding the definition and classification of hypertension.

1 reference

12 December 2020

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

1 reference

12 December 2020

Small artery remodeling is the most prevalent (earliest?) form of target organ damage in mild essential hypertension

1 reference

12 December 2020

Losartan and lercanidipine attenuate low-density lipoprotein oxidation in patients with hypertension and type 2 diabetes mellitus: a randomized, prospective crossover study

1 reference

12 December 2020

Enalapril. A reappraisal of its pharmacology and therapeutic use in hypertension

1 reference

12 December 2020

Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV.

1 reference

12 December 2020

Nephroprotective effect of treatment with calcium channel blockers in spontaneously hypertensive rats.

1 reference

12 December 2020

A double blind randomized trial to compare the effects of eprosartan and enalapril on blood pressure, platelets, and endothelium function in patients with essential hypertension

1 reference

12 December 2020

Bradykinin stimulates the release of tissue plasminogen activator in human coronary circulation: effects of angiotensin-converting enzyme inhibitors

1 reference

12 December 2020

Effects of candesartan cilexetil and enalapril on inflammatory markers of atherosclerosis in hypertensive patients with non-insulin-dependent diabetes mellitus

1 reference

12 December 2020

2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension

1 reference

12 December 2020

10.2165/00003495-200767010-00007

Identifiers

DOI

1 reference

Dimensions Publication ID

15 August 2017

1043891425

0 references

1 reference